Recombinant Escherichia coli Cytosine deaminase/CodA Protein，His & SUMO

Cytosine deaminase (CDA), also known as CodA, is an enzyme that catalyzes the deamination of cytosine to uracil, playing a pivotal role in nucleic acid metabolism and the regulation of nucleotide pools in various organisms. The study of CDA has gained significance in the context of cancer therapy, particularly in the development of suicide gene therapies, where the enzyme converts a non-toxic prodrug into a toxic metabolite specifically within tumor cells. This targeted approach enhances the therapeutic efficacy while minimizing systemic toxicity. Additionally, CDA is of interest in synthetic biology, where its ability to manipulate nucleotides can be utilized for creating novel biosynthetic pathways and metabolic engineering. Researchers have focused on characterizing and optimizing CodA through recombinant protein expression techniques, enhancing its stability, activity, and substrate specificity. Such studies involve the cloning of the CDA gene, expression in suitable host organisms, and subsequent purification of the protein. Understanding the structure-function relationships of CDA not only facilitates its application in medical and biotechnological fields but also deepens our comprehension of evolutionary adaptation and enzyme mechanisms. The exploration of CDA and its recombinant forms opens avenues for innovative treatments and biotechnological applications, making it a key focus for ongoing research in enzymology and gene therapy.